Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1247-000

Question

  1. What is the clinical effectiveness of the combination of ivabradine and sacubitril/valsartan for the treatment of heart failure?
  2. What are the evidence-based guidelines regarding the combination of ivabradine and sacubitril/valsartan for the treatment of heart failure?

Key Message

No evidence was identified regarding the clinical effectiveness of combined ivabradine and sacubitril/valsartan for the treatment for heart failure and no evidence-based guidelines regarding the combination of ivabradine and sacubitril/valsartan for the treatment of heart failure were identified.

Files

Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines Rapid Response February 13, 2020 View PDF
Last Updated : February 24, 2020